(TheNewswire)
|
|||||||||
|
|
|
|||||||
Kelowna, BC – March 4, 2025 – TheNewswire - Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU7) (“Doseology” or the “Company”), an innovator in precision-formulated performance solutions, is pleased to announce the launch of Doseology USA Inc. , a wholly owned subsidiary based in Florida . This strategic expansion marks Doseology’s official entry into the multi-billion-dollar U.S. market and reinforces its commitment to developing next-generation oral stimulants designed to enhance energy, focus, and cognitive performance .
High-Growth Market Opportunity
The Modern Oral Stimulant Market is experiencing rapid expansion as consumers demand precision-dosed, clean, and effective alternatives to coffee, energy drinks, and tobacco-based nicotine.
Pouches are emerging as the dominant delivery format , offering a discreet, portable, and efficient solution. With sustained-release technology , they provide long-lasting effects without spikes or crashes—ideal for today’s active consumers. Unlike traditional energy products, they deliver zero-calorie, sugar-free stimulation without the downsides of caffeine crashes or excessive sugar intake.
This shift is fueling explosive growth across three key categories:
-
Caffeine Pouches – A tobacco-free solution for clean, sustained energy.
-
Nicotine Synthetic Nicotine Pouches – Driving mass adoption in smoke-free alternatives.
-
Adaptogenic Functional Pouches – Infused with nootropics for enhanced cognitive performance and stress resilience.
As demand surges, pouches are redefining the future of modern oral stimulants —creating high-impact opportunities for investors and innovators alike.
Scientific research continues to validate the cognitive and performance benefits of stimulants when used responsibly .
*Caffeine enhances alertness, athletic performance, and
metabolism (
National
Institutes of Health, 2022
).
*Nicotine (including synthetic nicotine) has been linked to improved
focus, cognitive enhancement, and mood regulation (
Harvard Medical School, 2021
).
*Adaptogens & nootropics are being integrated into functional
products to boost mental clarity, sustained energy, and stress
resilience.
As consumer demand for controlled-dosing, bioavailable stimulants increases, next-generation delivery formats like pouches are reshaping the industry, providing more effective, convenient, and refined stimulant experiences.
Pouch Market Expansion
-
Global caffeine market to grow from $16.98B (2023) to $28.52B (2030) ( Coherent Market Insights ).
-
Nicotine pouch market projected to reach $22.84B by 2030, at a 34.4% CAGR ( Grand View Research ).
-
Synthetic nicotine market to hit $2.98B by 2028, expanding at 23.4% CAGR ( Growth Market Reports ).
-
Adaptogenic functional stimulant market is surging as consumers seek natural cognitive enhancers.
As the modern oral stimulant market evolves, Doseology is leveraging its expertise in precision dosing and advanced delivery systems to strengthen its footprint across North America. With its tincture line already available in major National Canadian Retailers , the company is expanding its retail presence and product innovation pipeline to seize new market opportunities.
"Fueled by next-generation technologies and backed by cutting-edge science, Doseology plans to revolutionise the product experience with unmatched results," said Dan Vice, Co-Founder & Director. "By redefining delivery and formulation, we are setting bold new industry standards— powered by Doseology —while seamlessly integrating into established retail networks across North America."
Beyond organic expansion, Doseology is actively pursuing strategic acquisitions to strengthen its supply chain, innovation pipeline, and scalability. By integrating value-add verticals, the Company follows the path of industry leaders who use acquisitions to optimize operations, expand efficiency, and drive long-term value.
This strategy ensures Doseology remains at the forefront of high-performance oral stimulants, capitalizing on a multi-billion-dollar market opportunity.
Market References & Data Sources
-
Caffeine Market Growth Coherent Market Insights
-
Nicotine Pouch Market Growth Grand View Research
-
Synthetic Nicotine Market Growth Growth Market Reports
-
Nicotine Pouches Market Expansion Financial Times
-
Synthetic Nicotine Adoption Reuters
Capital Investment
The capital raised will be invested to accelerate product innovation, scale distribution, drive consumer adoption, and expand investor awareness efforts across European, U.S. and Canadian markets.
The private placements are subject to Canadian Securities Exchange approval, with a hold period of four months and one day from issuance.
To support its growth strategy, Doseology is raising up to $1,900,000 through two non-brokered strategic private placements:
$900,000 Private Placement (“First Tranche Private Placement”)
-
Offering consists of up to 10,000,000 million units at $0.09 per unit.
-
Each unit includes:
-
One common share of the Company.
-
One purchase warrant, exercisable for one additional share at $0.12 per share for 2 years.
-
$1,000,000 Private Placement (“Second Tranche Private Placement”)
-
Offering consists of up to 4,000,000 subscription receipts at $0.25 per subscription receipt.
-
Upon meeting escrow release conditions, each subscription receipt converts into:
-
One common share of the Company.
-
One purchase warrant, each exercisable at $0.50 for 2 years, subject to an early acceleration provision.
-
The escrow release conditions for the Second Tranche Private Placement will be the receipt of Canadian Securities Exchange (“CSE”) approval, shareholder approval (if necessary) and the attainment of certain performance based milestones for Doseology USA Inc.
The securities underlying the Placements shall be subject to CSE approval and shall have a hold period equal to four months and one day from the date of issuance.
About Doseology Sciences Inc.
Doseology is a performance-driven innovation company at the intersection of biotechnology and advanced delivery systems, engineering precision-formulated oral stimulants that optimize energy, focus, and cognitive performance. Through science-backed research and cutting-edge formulation technologies, the Company is pioneering next-generation performance solutions that empower consumers to perform at their peak.
For more information, visit www.doseology.com
On Behalf of the Board of Directors
Dan Vice, Co-Founder Director
Doseology Sciences Inc.
Contact
¿¿hello@doseology.com
Disclaimer
This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR .
No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Copyright (c) 2025 TheNewswire - All rights reserved.
